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Abstract
Purpose Better breast cancer prognostication may
improve selection of patients for adjuvant therapy. We
conducted a retrospective longitudinal study in which we
investigated sera of high-risk primary breast cancer
patients, to search for proteins predictive of recurrence-free
survival.
Methods Sera of 82 breast cancer patients obtained after
surgery, but prior to the administration of adjuvant therapy,
were fractionated using anion-exchange chromatography,
to facilitate the detection of the low-abundant serum
peptides. Selected fractions were subsequently analysed by
surface-enhanced laser desorption/ionisation time-of-flight
mass spectrometry (SELDI-TOF MS), and the resulting
protein profiles were searched for prognostic markers by
appropriate bioinformatics tools.
Results Four peak clusters (i.e. m/z 3073, m/z 3274, m/z
4405 and m/z 7973) were found to bear significant prog-
nostic value (P B 0.01). The m/z 3274 candidate marker
was structurally identified as inter-alpha-trypsin inhibitor
heavy chain 4 fragment658–688 in serum. Except for the m/z
7973 peak cluster, these peaks remained independently
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associated with recurrence-free survival upon multivariate
Cox regression analysis, including clinical parameters of
known prognostic value in this study population.
Conclusion Investigation of the postoperative serum
proteome by, e.g., anion-exchange fractionation followed
by SELDI-TOF MS analysis is promising for the detection
of novel prognostic factors. However, regarding the rather
limited study population, validation of these results by
analysis of independent study populations is warranted to
assess the true clinical applicability of discovered prog-
nostic markers. In addition, structural identification of the
other markers will aid in elucidation of their role in breast
cancer prognosis, as well as enable development of abso-
lute quantitative assays.
Keywords Breast cancer  Recurrence-free survival 
Prognostic markers  Serum  Anion-exchange fractionation
 SELDI-TOF MS
Introduction
Breast cancer is at present the most commonly diagnosed
neoplasm among women (Jemal et al. 2008). In addition,
despite the substantial progress made in cancer therapy,
breast cancer is the second leading cause of female cancer
deaths, following lung cancer (Jemal et al. 2008). The main
prognostic factors currently used to determine eligibility
for administration of adjuvant systemic therapy include
both clinical and pathological parameters, e.g., patient’s
age at diagnosis, tumour size, lymph node status, grade of
malignancy (Goldhirsch et al. 2003). However, despite
appropriate locoregional treatment and adjuvant systemic
therapy, 30–50% of breast cancer patients will develop
metastatic relapse and die (Early Breast Cancer Trialists’
Collaborative Group 1998), while there is a substantial
percentage of patients that would have survived without
adjuvant chemo- and hormonal therapy. Evidently, cur-
rently applied prognostic markers do not suffice for precise
risk-group determination in breast cancer. This failure most
likely originates in the high molecular heterogeneity of
breast cancer pathogenesis and progression, which the
currently used prognostic parameters clearly cannot fully
address. Improved prognostic markers that might help to
reduce both over- and undertreatment of the disease are
thus urgently needed.
In search for these markers, investigators from our
institutes have published gene expression profiles in
tumour tissue that outperformed all prognostic parameters
in predicting disease outcome (i.e. distant metastases) (‘t
Veer et al. 2002; Foekens et al. 2006; van de Vijver et al.
2002; Wang et al. 2005). Nonetheless, it is currently
understood that the functional ‘‘end-unit’’ of the genome,
i.e., the proteome, might have greater ability in reflecting
the molecular complexity of (breast) cancer. Covering
posttranslational and posttranscriptional modifications, the
proteome reflects both the intrinsic genetic programme of
the cell and the impact of its immediate environment,
providing a highly dynamic and accurate view of a bio-
logical status (Banks et al. 2000) and, hence, a rich and
complementary source of potential biomarkers.
One of the proteomic technologies used extensively in
the search for novel markers is surface-enhanced laser
desorption/ionisation time-of-flight mass spectrometry
(SELDI-TOF MS) (Hutchens and Yip 1993). By com-
bining retention chromatography with laser desorption/
ionisation MS instrumentation, this platform has enabled
high-throughput mass profiling of highly complex bio-
logical samples, such as tissue lysates and serum. Thus
far, only two studies have reported the use of SELDI-TOF
MS for discovery of prognostic breast cancer markers
(Goncalves et al. 2006; Ricolleau et al. 2006). Ricolleau
et al. (2006) investigated tumour cytosolic extracts of 60
breast cancer patients and identified ubiquitin and ferritin
light chain to be associated with prognosis. Goncalves
et al. (2006), on the other hand, investigated serum, being
an easier accessible biological matrix that provides a good
reflection of the human proteome as it perfuses all tissues
of the body. Following SELDI-TOF MS analysis of
fractionated sera, they constructed a multiprotein model
consisting of 40 proteins, correctly predicting relapse in
67 of 81 patients (Goncalves et al. 2006). Our research
group has previously performed a prognostic SELDI-TOF
MS study in serum as well (Gast et al. 2009). Although
we initially discovered the haptoglobin phenotype to be a
strong, independent, prognostic parameter in high-risk
primary breast cancer (n = 63), this result most likely was
false positive, as it was not confirmed following analysis
of our validation sample set (n = 371) (Gast et al. 2009).
In contrast to the study of Goncalves et al. (2006), we
investigated raw, unfractionated sera in our previous
study. While only 22 proteins comprise more than 99% of
the human serum proteome, the low-abundant proteins
make up for the remaining \1% (Anderson and Anderson
2002). This large dynamic range of proteins in crude
serum hampers detection of the allegedly high-informative
low-abundant serum proteins. Serum fractionation, how-
ever, is likely to facilitate detection of the low-abundant
proteins through reduction of this dynamic range (Hoff-
man et al. 2007).
Hence, by analysis of fractionated serum, we aimed to
obtain better sensitivity of detection of markers that can be
applied in the prognostication of breast cancer. To this end,
sera of 82 breast cancer patients procured after surgery, but
prior to the administration of adjuvant therapy, were frac-
tionated using anion-exchange chromatography. Selected
1774 J Cancer Res Clin Oncol (2011) 137:1773–1783
123
fractions were subsequently analysed by SELDI-TOF MS,
and resulting protein profiles were searched for prognostic
markers by appropriate bioinformatics tools.
Materials and methods
Study population
From 1993 to 1999, high-risk primary breast cancer
patients who had undergone a modified radical mastec-
tomy or breast conserving surgery with complete axillary
clearance participated in a randomised, multicentre, phase
III trial. This study investigated the benefit of high-dose
adjuvant chemotherapy in patients with C4 axillary lymph
node metastases. The design of the study has been
described elsewhere (Rodenhuis et al. 2003). Major eli-
gibility criteria were histologically confirmed stage 2A,
2B or 3A breast cancer with at least four tumour-positive
axillary lymph nodes, but no evidence of distant metas-
tases, age under 56 years, and no previous other
malignancies.
In the current study, sera of 82 study patients who were
treated in the Erasmus Medical Center–Daniel den Hoed
Cancer Center (Erasmus: n = 24), or in the Radboud
University Medical Center Nijmegen (Radboud: n = 58)
were included. Sera were obtained after surgery
(13–55 days), but prior to the administration of adjuvant
chemotherapy (0–41 days), and all sera were stored at -
80C. All serum samples were obtained with medical ethics
approval, and all patients gave informed consent.
Chemicals
All used chemicals were obtained from Sigma, St. Louis,
MO, USA, unless stated otherwise.
Serum fractionation
Sera were fractionated manually using a strong anion-
exchange Q ceramic resin (Bio-Rad Labs, Hercules, CA,
USA), according to manufacturers’ protocol. Briefly, sera
(20 ll) were denatured in 9 M urea/2% 3[(3-cholamido-
propyl)-dimethylammonio]-propane sulphonate (CHAPS),
after which they were randomly allocated in duplicate to
two 96-well ProteinChip Q filtration plates, prefilled with
Q ceramic HyperD F resin (Bio-Rad Labs). In addition, one
serum sample was randomly assigned to 12 different wells
of each fractionation plate for quality control purposes.
Following incubation (30 min), the flow through was col-
lected using a vacuum manifold (Millipore, Billerica, MA,
USA). Bound proteins were subsequently eluted with a
stepwise pH gradient using wash buffers ranging from pH 9
to pH 3, followed by an organic buffer for elution of
remaining proteins. As a result, six serum fractions
(F) were obtained, i.e., F1 (flow-through plus pH 9), F2
(pH 7), F3 (pH 5), F4 (pH 4), F5 (pH 3) and F6 (organic
buffer). Prior to protein profiling, fractions were stored
overnight at ?4C.
SELDI-TOF MS protein profiling
Protein profiling of serum fractions was performed using
the ProteinChip SELDI (PCS 4000) Reader (Bio-Rad
Labs). Various array chemistries and fractions were ini-
tially evaluated to determine which combination provided
the best protein profiles in terms of number and resolution
of proteins. Following assay optimisation, we selected
Immobilized Metal Affinity Capture (IMAC30) arrays for
the analysis of F3 and F4 and weak cation-exchange
(CM10) arrays for the analysis of F5 and F6. Throughout
the manual assay, arrays were assembled in a 96-well
bioprocessor, which was shaken on a MicroMix 5 platform
shaker (DPC Cirrus Inc., Los Angeles, CA, USA) at setting
20/7.
IMAC30 arrays were charged with 50 ll of 100 mM
copper sulphate (Merck, Darmstadt, Germany) for 10 min,
followed by neutralisation (5 min) with 200 ll 100 mM
sodium acetate buffer pH 4. Next, both IMAC30 and CM10
arrays were equilibrated twice for 5 min with 200 ll of
their respective binding buffers (IMAC30: 0.01 M phos-
phate-buffered saline pH 7.4/0.5 M sodium chloride
(Merck), CM10: 20 mM sodium acetate pH 4). Arrays
were subsequently loaded with 85 ll of binding buffer and
15 ll of the fractionated sample. After incubation
(30 min), arrays were washed three times with 200 ll of
binding buffer, and following a quick rinse with MilliQ
water (Millipore), arrays were air-dried. A 50% sinapinic
acid (Bio-Rad Labs) solution in 50% acetonitrile (Lab-scan
Ltd., Dublin, Ireland)/0.5% trifluoroacetic acid (Merck)
was applied twice (1.0 ll) to the arrays as the matrix.
Following air-drying, the arrays were analysed using the
ProteinChip SELDI (PCS 4000) Reader. Data were col-
lected between 0 and 300 kDa, averaging 530 laser shots
with 3,500 nJ intensity, at focus mass 7.5 kDa and matrix
attenuation 1,000 Da. For mass accuracy, the instrument
was calibrated on the day of measurements with All-in-One
protein standard (Bio-Rad Labs).
Statistics and bioinformatics
Mass spectrometry data were processed using the tbimass
R-package (http://www.r-project.org, publication in prepa-
ration). After pre-processing (resampling, baseline correc-
tion, normalisation and alignment correction), peaks were
recognised using PROcess (http://www.bioconductor.org)
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on the mean spectra of each experimental group (fraction/
ProteinChip array type). For the discovery of peak clusters
with significant prognostic value, a subpopulation (n = 68)
containing patients diagnosed with a recurrence within
36 months of follow-up (n = 32) and patients experiencing
no recurrence after a follow-up of at least 48 months
(n = 36) were extracted from the study population
(n = 82). By investigating this subpopulation using Cox
proportional hazards analysis, the peak clusters associated
with recurrence were identified within all peaks of the
combined data of all fractions/ProteinChip array types. For
selection, a stepwise method was applied (i.e. stepBIC), an
algorithm sequentially searching through all possible Cox
proportional hazard models for the one that minimises the
Bayesian Information Criterion (BIC). Recurrence-free
survival was calculated from the date of randomisation to
the time of first recurrence or death, or the date of last
follow-up.
Clinical parameters were selected for known impact on
recurrence in the study population, to prevent overfitting of
the data by the model. To this end, a Cox proportional
hazards analysis was performed including the known
clinical parameters presented in Table 1, based on forward
entry (P \ 0.05). In addition, results were adjusted for
treatment allocation as in the original clinical trial. The
obtained model was subsequently applied to the study
population.
A Cox proportional hazards model was subsequently
build on the total study population, by inclusion of the
relevant clinical parameters only. To investigate whether
the relationship between peak intensities and recurrence-
free survival could be explained by any of the relevant
clinical parameters, the hazard ratios were adjusted for
these clinical parameters by construction of a Cox pro-
portional hazards model on the study population, incor-
porating the selected peak clusters and the relevant clinical
parameters.
Since our study population originated from two dif-
ferent hospitals that allegedly used different sample col-
lection protocols, our results could have been influenced
by various pre-analytical factors. The influence of the
different collection protocols on the SELDI-TOF MS
protein profiles was investigated by multidimensional
scaling of the SELDI-TOF MS spectra. Herewith, the
degree of similarity or dissimilarity between the samples
withdrawn at the two different hospitals is graphically
expressed: points representing similarity tend to cluster
together, while points representing dissimilarity tend to be
far apart. The influence of collection centre on the protein
profile was furthermore investigated by Cox proportional
hazards analysis for each peak cluster separately, incor-
porating one peak cluster, relevant clinical parameters and
collection centre.
The reproducibility of the assay was assessed by anal-
ysis of one quality control serum sample, fractionated 24
times by random assignment to 12 different wells of each
of the two fractionation plates. Within the quality control
spectra, all peaks with a signal-to-noise ratio (S/N) C2
were detected, after which the coefficient of variation was
calculated on the corresponding peak intensities. Finally,
for the candidate biomarkers, the per cent difference
between replicates, divided by the mean peak intensity,
was calculated for all replicates measured in the study
population. All statistical tests were two sided, and
P \ 0.05 was considered statistically significant.
Peptide identification
For identification purposes, peptides of interest were
extracted from serum (fractions) by reversed-phase C18
magnetic beads (Dynabeads RPC18, Invitrogen, Breda,
The Netherlands) using a Kingfisher 96 liquid handling
system (Thermo Fisher Scientific, Waltham, MA, USA),
according to the optimized protocol described in (Jimenez
et al. 2007). Briefly, sera were diluted in TFA 0.1%, after
which the peptide content was bound to the beads. The
beads were subsequently washed with 0.1% TFA and
eluted with 50% ACN. Eluate (1 ll) was mixed with
a-cyano-4-hydroxy-cinnamic acid matrix (2 ll), after which
the mixture was spotted (0.7 ll) on a MALDI target plate.
Analyses were performed on a 4800 MALDI-TOF/TOF
mass spectrometer (Applied Biosystems, Foster City,
CA, USA). Fragment ion spectra were taken to search the
NCBI 20081128 database (Homo sapiens: 216937 sequen-
ces) using the MASCOT search engine at http://www.
matrixscience.com (Matrix Science Ltd., London, UK), with
the following search parameters: monoisotopic precursor
mass tolerance: 18 ppm, fragment mass tolerance: 1 Da,
variable modifications: methionine oxidation, and no spec-
ified protease cleavage site.
Results
Study population
At time of analysis, 45 patients (Erasmus: 19 pts, Radboud:
26 pts) had a recurrence or had died and 37 patients
(Erasmus: 5 pts, Radboud: 32 pts) were censored at a
median follow-up of 6.5 years (Erasmus: 7.8 years, Rad-
boud: 6.3 years). Patient characteristics are provided in
Table 1. All patient characteristics were similarly distrib-
uted between the samples obtained from the Erasmus
Medical Center and the Radboud University Medical
Center, as determined by the chi-squared test or the Mann–
Whitney U-test.
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SELDI-TOF MS protein profiling
Out of the 400 peak clusters tested for inclusion into the
model, four peak clusters [m/z 3073 (F4/IMAC30), m/z
3274 (F4/IMAC30), m/z 4404 (F6/CM10), m/z 7973 (F5/
CM10)] were selected due to their significant association
with recurrence-free survival in the subpopulation
(Table 2). A representative example of SELDI-TOF MS
protein profiles is depicted in Fig. 1.
The parameters ‘age’ (\40 years, P = 0.021), ‘number
of positive lymph nodes’ (C10, P = 0.012), and ‘proges-
terone receptor status’ (negative, P = 0.003) showed to be
significantly associated with reduced recurrence-free sur-
vival in the study population. In addition, the parameter
Table 1 Patient and tumour
characteristics of the study
population
Erasmus (n = 24) Radboud (n = 58) Total (n = 82)
n (%) n (%) n (%)
Patient characteristics
Age, mean (range) 43.5 (26–54) 43.2 (28–54) 43.3 (26–54)
\40 years 6 (25) 15 (26) 21 (26)
C40 years 18 (75) 43 (74) 61 (74)
Menopausal status
Premenopausal 21 (88) 52 (90) 73 (89)
Postmenopausal 3 (12) 5 (9) 8 (10)
Unknown 0 (0) 1 (1) 1 (1)
Surgery
Mastectomy 15 (63) 40 (69) 55 (67)
Breast conserving 9 (37) 18 (31) 27 (33)
Treatment
Conventional dose 13 (54) 30 (52) 43 (52)
High dose 11 (46) 28 (48) 39 (48)
Tumour characteristics
Number of positive lymph nodes
4–9 15 (63) 38 (66) 53 (65)
C10 9 (37) 20 (34) 29 (35)
Tumour size
T1 (\2 cm) 7 (29) 17 (29) 24 (29)
T2 (2–5 cm) 13 (54) 34 (59) 47 (57)
T3 (C5 cm) 4 (17) 7 (12) 11 (14)
Her2/neu status
Negative 13 (54) 37 (64) 50 (61)
Positive 10 (42) 19 (33) 29 (35)
Unknown 1 (4) 2 (3) 3 (4)
Oestrogen receptor status
ER negative 9 (38) 23 (40) 32 (39)
ER positive 14 (58) 35 (60) 49 (60)
Unknown 1 (4) 0 (0) 1 (1)
Progesterone receptor status
PR negative 10 (42) 24 (41) 34 (42)
PR positive 13 (54) 34 (59) 47 (57)
Unknown 1 (4) 0 (0) 1 (1)
Bloom-Richardson grade
Grade I 0 (0) 7 (12) 7 (9)
Grade II 6 (25) 18 (31) 24 (29)
Grade III 17 (71) 32 (55) 49 (60)
Unknown 1 (4) 1 (2) 2 (2)
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‘treatment’ was included to correct for the different treat-
ment arms of the original clinical trial. Three of the four
selected peak clusters (i.e. m/z 3072, m/z 3274 and m/z
4404) remained significantly associated with recurrence-
free survival in combination with the clinical variables
(Table 2).
Furthermore, using multidimensional scaling, we
investigated the association of the different collection
protocols (allegedly used by the two hospitals) on the
SELDI-TOF MS serum protein profiles. As depicted in
Fig. 2 for F4/CM10, spectra of the sera collected in the
Erasmus Medical Center and the Radboud University
Medical Center are randomly distributed, indicating no
structural differences in the SELDI-TOF MS serum protein
profiles of both hospitals. In addition, following Cox pro-
portional hazards analysis including one peak cluster, rel-
evant clinical parameters and collection centre, all peak
clusters except m/z 7973, remained (borderline) significant
(i.e. m/z 3073: HR = 3.44, P = 0.046, m/z 3274: HR =
2.39, P = 0.051, m/z 4405: HR = 0.107, P \ 0.001, and
m/z 7973: HR = 0.35, P = 0.160).
The reproducibility of the assay was investigated by
calculation of the coefficient of variation of all peak
clusters with S/N [2 detected in the quality control
spectra (n = 24 per fraction/ProteinChip array type)
(Fig. 3). The median coefficient of variation of the peak
intensities following fractionation and SELDI-TOF MS
analysis ranged from 13.4 to 24.2% for the different
fractions/ProteinChip arrays investigated, with an overall
average CV of 20.2%. Of the four candidate markers
measured in the study population, the median per cent
difference in peak intensity between the replicates, divi-
ded by the mean peak intensity, ranged from 20 to 25%
(Fig. 4).
Peptide identification
The MALDI serum(fraction) peptide profiles obtained
after C18 magnetic bead-assisted peptide captures were
searched for the presence of prognostic SELDI peaks
based on mass matching. Due to the different chemistries
used for peptide capture for SELDI-TOF MS (IMAC30
Cu) and MALDI-TOF MS (C18) and to the mass limi-
tations for direct fragmentation, we were able to elucidate
the identity of one of the four candidate prognostic peak
clusters in the spectra of whole serum. The SELDI-TOF
MS peak cluster at m/z 3274 was detected by MALDI-
TOF/TOF MS as MH? ions at m/z 3271.69 (default cal-
ibration) and identified by MALDI-TOF/TOF MS/MS
(Fig. 5) in conjunction with database searching as a
Table 2 Multivariate proportional hazards analyses for the risk of
recurrence on selected peak clusters, before (model 1, subpopulation)
and after (model 3, total study population) adjustment for relevant
clinical parameters, and on relevant clinical parameters solely (model
2, total study population)
Parameter Model 1—peak clusters Model 2—clinical parameters Model 3—combined
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Peak cluster
m/z 3073 3.17 (2.03–4.96) \0.001 2.48 (1.78–3.48) \0.001
m/z 3274 10.18 (1.99–52.01) 0.005 11.71 (2.05–66.90) 0.006
m/z 4405 0.02 (0.01–0.25) 0.003 0.01 (0.01–0.17) 0.001
m/z 7973 0.05 (0.01–0.48) 0.010 0.24 (0.03–1.78) 0.160
Treatment
CONV 1 – – 1 – –
HD 1.59 (0.86–2.95) 0.140 2.48 (1.24–4.98) 0.011
Age
\40 years 1 – – 1 – –
C40 years 0.44 (0.22–0.88) 0.021 0.35 (0.16–0.74) 0.006
No. of LN?
C10 1 – – 1 – –
4–9 0.44 (0.23–0.84) 0.012 0.37 (0.19–0.72) 0.003
PR status
PR(-) 1 – – 1 – –
PR(?) 0.40 (0.22–0.73) 0.003 0.28 (0.14–0.55) \ 0.001
CONV conventional dose arm, HD high-dose arm, LN? number of positive lymph nodes, PR progesterone receptor status positive (?) and
negative (-)
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fragment of inter-alpha-trypsin inhibitor heavy chain 4
(ITIH4658–688), with a MASCOT score of 69 (expect:
0.0025).
Discussion
In the current study, we investigated sera of 82 breast
cancer patients obtained after surgery, but prior to the
administration of adjuvant therapy, in search for novel
prognostic biomarkers. To facilitate the detection of the
low-abundant serum peptides, sera were fractionated using
anion-exchange chromatography, after which selected
fractions were analysed by SELDI-TOF MS. Resulting
protein profiles were searched for prognostic markers by
appropriate bioinformatics tools. Considering solely the
peak clusters detected in the SELDI-TOF MS protein
profiles, four peak clusters (i.e. m/z 3073, m/z 3274, m/z
4405 and m/z 7973) were found to bear significant prog-
nostic value, also after adjustment for known clinical
prognostic parameters. The m/z 3274 candidate marker was
structurally identified as ITIH4658–688 in serum. Hence,
investigation of the postoperative serum proteome by, e.g.,
anion-exchange fractionation, followed by SELDI-TOF
MS analysis, is promising for the detection of novel
prognostic factors. However, regarding the rather limited
study population, validation of our results by analysis of
similar, prospectively collected, independent, study popu-
lations is warranted to assess the true clinical applicability
Fig. 1 Representative example
of fractionated serum protein
profiles of two patients (pt A:
patient with no recurrence for
123 months, pt B: patient with a
recurrence at 54 months)
Fig. 2 MDS plot of Fraction 4/IMAC30 data (i.e. duplicate spectra)
on center of withdrawal (R Erasmus, N Radboud, O quality control
sample)
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of identified prognostic markers. In addition, structural
identification of the other markers will aid in elucidation of
their role in breast cancer prognosis, as well as enable
development of absolute quantitative assays (e.g. van den
Broek et al. 2008).
Metastases are thought to arise from clinically unde-
tectable residual or micrometastatic disease, activated by
a.o. stroma-generated growth factors, early impediment of
immune surveillance and enhancement of angiogenesis
(Demicheli et al. 1997, 2008; Heimann and Hellman 2000;
Pupa et al. 2002). These early postsurgical host response
processes are potentially affected by surgical extirpation of
the tumour, as this disrupts the intricate interactions
between malignant cells and physiological tumour-control
mechanisms (Fisher et al. 1989; Tagliabue et al. 2003).
Hence, the early postoperative serum proteome can bear
prognostic information, since it reflects the host response
processes that can play a key role in metastatic progression.
The candidate prognostic markers detected in the current
study therefore most likely correlate with this postoperative
host response. In addition, since all study participants were
treated with adjuvant chemotherapy, these differentially
expressed proteins may also relate to the tumour phenotype
and its chemosensitivity. Nonetheless, the four candidate
markers could also arise directly from residual or micro-
metastatic disease. Considering the nadir in tumour burden
following surgery, however, serum concentrations of
tumour-secreted proteins most likely are well below the
detection limit of the SELDI-TOF MS platform, even
following serum fractionation. Lastly, the four candidate
prognostic markers can also result from tumour-secreted
Fig. 3 Coefficient of variation
(y-axis) of the peak cluster
identified in the quality control
sample (x-axis) fractionated on
fractionation plate 1 (red) and
plate 2 (green)
Fig. 4 Percent difference in peak intensity between replicates,
divided by mean intensity, of the four candidate markers
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proteases that process host-response proteins upon their
exposure to the tumour microenvironment (Fung et al.
2005; Villanueva et al. 2006). Since these modified host
response proteins are generally present at substantially
higher circulatory concentrations than the enzymes that
process them upon their exposure to the tumour microen-
vironment, they can be detected in blood by SELDI-TOF
MS.
This latter hypothesis is in fact endorsed by the struc-
tural identity of the candidate m/z 3274 marker, i.e., the
inter-alpha-trypsin inhibitor heavy chain 4658–688 fragment,
identified in serum. We previously found serum levels of
this fragment decreased in breast cancer compared to
control. Other studies have detected this fragment in serum
as well, reporting either a lack of discriminative value
(Fung et al. 2005; Villanueva et al. 2006) or an increase in
breast cancer compared to control (Song et al. 2006). Most
likely, these contradictory findings originate from the het-
erogeneity of the different study populations investigated
or from the postulated instability of ITIH4 fragments (Fung
et al. 2005; Song et al. 2006; Timms et al. 2007). In
addition, changes in the abundance of the m/z 3274 ITIH4
fragment have been found associated with various types of
cancer (e.g. prostate, breast, ovarian, colorectal and pan-
creatic cancer) (Fung et al. 2005; Villanueva et al. 2006;
Song et al. 2006). This evident lack of specificity does not
hamper its use as prognostic marker, however. The various
serum ITIH4 fragments are currently hypothesised to result
from tumour-secreted proteases that process host response
proteins upon their exposure to the tumour microenviron-
ment (Fung et al. 2005; Song et al. 2006; Villanueva et al.
2005). Hence, in the current study, the m/z 3274 marker
could well originate from proteolytic activity associated
with residual (micrometastatic) disease. According to this
hypothesis, this candidate prognostic marker may be of
value in other malignancies as well, as the protease activity
has been shown to be cancer-type specific (Fung et al.
2005; Villanueva et al. 2006; Song et al. 2006). Hence,
future validation studies should also include other types of
malignancies.
Structural identification is imperative to investigate
origin and function of the other three candidate biomarkers.
In addition, concerning the rather limited study population,
results must be validated by analysis of an independent,
similar, sample set. However, such validation sets may
prove difficult to obtain regarding the extended follow-up
window needed to reliably investigate breast cancer
prognosis.
While serum is generated by coagulation, its proteome is
prone to the proteases involved in this cascade, as well as
to those involved in the complement cascade, activated
upon clotting. Various pre-analytical parameters, such as
sampling device, clotting temperature and storage time, can
thus all exert a distinct influence on the serum proteome.
Since our study populations originated from two different
hospitals that allegedly used different sample collection
protocols, our results could have been influenced by the
various pre-analytical factors. However, as depicted in
Fig. 2, we did not observe such an influence on the protein
profiles, indicating that the investigated serum proteome
most likely is rather robust to (small) differences in
collection protocols. Moreover, despite the different
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characteristics of the two study groups, all peak clusters
except m/z 7973 remained (borderline) significant after
inclusion of the collection centre in the Cox proportional
hazards model. The three peaks are therefore of additional
prognostic value, even if the different collection centres
are taken into account. The reliability of our results is
furthermore endorsed by the reproducibility of the assay
(average CV: 20.2%), which is well in agreement with
previous reports (Goncalves et al. 2006; Albrethsen
2007).
Conclusion
In conclusion, using serum anion-exchange fractionation in
combination with SELDI-TOF MS analysis, we discovered
4 peak clusters, one of which identified as serum
ITIH4658–688, with significant prognostic value in a study
population of 82 high-risk primary breast cancer patients.
Three peak clusters (including ITIH4658–688) remained
significantly associated with recurrence-free survival after
adjustment for clinical parameters. These results are
promising, as the prognostic profile identified in the current
study could eventually improve patient selection. However,
external validation using quantitative assays and elucida-
tion of biological mechanisms are warranted.
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